October 9, 2007 -- WuXi PharmaTech, the very successful Shanghai-based contract research organization, has begun construction of a GLP center in Suzhou. The 267,000 square foot facility will house a state-of-the-art preclinical drug safety evaluation center providing toxicology services. As a stock, WuXi has performed extremely well since its IPO. More details...
